When was Achilles Therapeutics founded?

Achilles Therapeutics was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Achilles Therapeutics located?

Achilles Therapeutics is headquartered in London, United Kingdom. It is registered at Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, England, SG1 2FX.

Who is the current CEO of Achilles Therapeutics?

Iraj Ali of Achilles Therapeutics.

Which legal entities is Achilles Therapeutics associated with?

Achilles Therapeutics is associated with Achilles Therapeutics Limited and 1 other.

How many employees does Achilles Therapeutics have?

As of Sep 30, 2026, the latest employee count at Achilles Therapeutics is 33.

Is Achilles Therapeutics a funded company?

Achilles Therapeutics is a funded company, having raised a total of $242M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 24, 2016.

When was the latest funding round of Achilles Therapeutics?

Achilles Therapeutics' latest funding was a $***** Grant (prize money) round on Jul 21, 2022, with participation from 1 investor.

Where does Achilles Therapeutics rank among its competitors?

Achilles Therapeutics ranks 512th amongst 3418 active competitors, of which 1150 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Achilles Therapeutics?

Achilles Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Achilles Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Achilles Therapeutics is a public company based in London (United Kingdom), founded in 2016 by Karl Peggs, Charles Swanton, Sergio Quezada, Mark Lowdell and Mark Lowdell. It operates as a Developer of T-cell therapies for cancer. Achilles Therapeutics has raised $242M in funding from investors like Orbimed, RA Capital Management and Syncona. The company has 3418 active competitors, including 1150 funded and 806 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of T-cell therapies for cancer. Its therapeutics will target tumor neo-antigens, unique flags to the immune system present on the surface of every cancer cell. They develop therapeutics for lung cancer, recurrent metastatic melanoma, and head and neck squamous cell carcinomas.

Website: achillestx.com
Social
Email ID: *****@achillestx.com
Registered Address: Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, England, SG1 2FX

Key Metrics

Founded Year

2016

Location

London, United Kingdom

Stage

Public

Total Funding

$242M in 5 rounds

Latest Funding Round

Grant (prize money), Jul 21, 2022, $*****

Investors

Orbimed & 42 more

Ranked

512^th among 3418 active competitors

Employee Count

33 as on Sep 30, 2026

Similar Companies

Senti Bio & 390 more

Exit Details

Public

View Achilles Therapeutics' full profile

Achilles Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ACHILLES THERAPEUTICS PLC CIN: 13027460 , United Kingdom, Active	Nov 17, 2020	-	-
Achilles Therapeutics Limited CIN: 10167668 , United Kingdom, Active	May 05, 2016	£0 - £1M (As on Sep 30, 2018)	118 (As on Dec 31, 2020)

Achilles Therapeutics got listed on Mar 31, 2021.

Click here to take a look at Achilles Therapeutics's IPO in detail

Achilles Therapeutics has raised a total funding of $242M over 5 rounds. Its first funding round was on May 24, 2016. Its latest funding round was a Grant (prize money) round on Jul 21, 2022 for $*****. 1 investor participated in its latest round. Achilles Therapeutics has 15 institutional investors and 28 angel investors.

Here is the list of recent funding rounds of Achilles Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 21, 2022	7573540	Grant (prize money)	4719955	6733676	1794999	7043071
Jun 01, 2021	3867538	Grant (prize money)	4690136	5640310	6911854	Europa
Nov 17, 2020	4789164	Series C	1943528	3605010	Orbimed & 1 more	RA Capital Management & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Achilles Therapeutics's funding rounds and investors

The founders of Achilles Therapeutics are Karl Peggs, Charles Swanton, Sergio Quezada, Mark Lowdell and Mark Lowdell.

Here are the details of Achilles Therapeutics' key team members:

Karl Peggs: Co-Founder of Achilles Therapeutics. They serve on the board of 1 company.
Charles Swanton: Co-Founder of Achilles Therapeutics.
Sergio Quezada: Co-Founder of Achilles Therapeutics.
Mark Lowdell: Co-Founder of Achilles Therapeutics.
Mark Lowdell: Co-Founder of Achilles Therapeutics.

Achilles Therapeutics' Board of Directors

Achilles Therapeutics's board has 8 active members. Michael Giordano, Karl Peggs, Derek Dirocco, Iraj Ali and Edwin Moses are part of team and Martin Murphy, Rogier Rooswinkel and Carsten Boess are independent board members.

Here is the list of Achilles Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
Karl Peggs	Team	-	Current	10y 3m
qdmouyx	Team	-	Current	2y 7m
qfnabcj	Team	-	Current	5y 7m
zxrlozf	Team	-	Current	9y 7m
zqsmr{q	Team	-	Current	7y 6m
xwxppxk	Team	-	Past	7y 3m
Martin Murphy	Independent board member	-	Current	8y 7m
xwlighh	Independent board member	-	Current	7y 2m
udpoxnp	Independent board member	-	Current	4y 8m
{ulwfqk	Independent board member	-	Past	3y 8m
sxgbbq{	Independent board member	-	Past	7y 5m
htcixxz	Independent board member	-	Past	1y 7m

View details of Achilles Therapeutics's Founder profiles and Board Members

Achilles Therapeutics' employee count trend

Achilles Therapeutics has 33 employees as of Sep 26. Here is Achilles Therapeutics's employee count trend over the years:

Employee count trend for Achilles Therapeutics

Uncover Achilles Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Achilles Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Achilles Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
512th	Achilles Therapeutics 2016, London (United Kingdom), Public	Developer of T-cell therapies for cancer	$242M	HTIF, Boxer Capital & 41 others	51/100